McElroy William T, Tan Zheng, Ho Ginny, Paliwal Sunil, Li Guoqing, Seganish W Michael, Tulshian Deen, Tata James, Fischmann Thierry O, Sondey Christopher, Bian Hong, Bober Loretta, Jackson James, Garlisi Charles G, Devito Kristine, Fossetta James, Lundell Daniel, Niu Xiaoda
Discovery Chemistry, Structural Chemistry, In Vitro Pharmacology, and Respiratory and Immunology, Merck Research Laboratories , 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
ACS Med Chem Lett. 2015 May 12;6(6):677-82. doi: 10.1021/acsmedchemlett.5b00106. eCollection 2015 Jun 11.
IRAK4 is a critical upstream kinase in the IL-1R/TLR signaling pathway. Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders. A screening campaign identified a pyrazole class of IRAK4 inhibitors that were determined by X-ray crystallography to exhibit an unusual binding mode. SAR efforts focused on the identification of a potent and selective inhibitor with good aqueous solubility and rodent pharmacokinetics. Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogues generally having good rodent oral exposure but poor solubility. N-Alkyl piperidines exhibited excellent solubility and reduced exposure. Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active. Piperazine 32 was a potent enzyme inhibitor with good cellular activity. Compound 32 reduced the in vivo production of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.
IRAK4是白细胞介素-1受体/ Toll样受体(IL-1R/TLR)信号通路中的关键上游激酶。据推测,抑制IRAK4对自身免疫相关疾病的治疗有益。一项筛选活动鉴定出一类吡唑类IRAK4抑制剂,通过X射线晶体学确定其具有不同寻常的结合模式。构效关系研究致力于鉴定出一种具有良好水溶性和啮齿动物药代动力学的强效且选择性的抑制剂。吡唑C-3哌啶耐受性良好,N-磺酰基类似物通常具有良好的啮齿动物口服暴露量,但溶解度较差。N-烷基哌啶表现出优异的溶解度,但暴露量降低。具有N-1吡啶和氟苯基取代基的吡唑是活性最高的化合物之一。哌嗪32是一种具有良好细胞活性的强效酶抑制剂。化合物32可降低体内促炎细胞因子的产生,并且在小鼠抗体诱导的关节炎炎症疾病模型中口服有效。